Genetic Dissection of Azole Resistance Mechanisms in Candida albicans and Their Validation in a Mouse Model of Disseminated Infection
Open accessAbstract
Principal mechanisms of resistance to azole antifungals include the upregulation of multidrug transporters and the modification of the target enzyme, a cytochrome P450 (Erg11) involved in the 14alpha-demethylation of ergosterol. These mechanisms are often combined in azole-resistant Candida albicans isolates recovered from patients. However, the precise contributions of individual mechanisms to C. albicans resistance to specific azoles have been difficult to establish because of the technical difficulties in the genetic manipulation of this diploid species. Recent advances have made genetic manipulations easier, and we therefore undertook the genetic dissection of resistance mechanisms in an azole-resistant clinical isolate. This isolate (DSY296) upregulates the multidrug transporter genes CDR1 and CDR2 and has acquired a G464S substitution in both ERG11 alleles. In DSY296, inactivation of TAC1, a transcription factor containing a gain-of-function mutation, followed by sequential replacement of ERG11 mutant alleles with wild-type alleles, restored azole susceptibility to the levels measured for a parent azole-susceptible isolate (DSY294). These sequential genetic manipulations not only demonstrated that these two resistance mechanisms were those responsible for the development of resistance in DSY296 but also indicated that the quantitative level of resistance as measured in vitro by MIC determinations was a function of the number of genetic resistance mechanisms operating in any strain. The engineered strains were also tested for their responses to fluconazole treatment in a novel 3-day model of invasive C. albicans infection of mice. Fifty percent effective doses (ED(50)s) of fluconazole were highest for DSY296 and decreased proportionally with the sequential removal of each resistance mechanism. However, while the fold differences in ED(50) were proportional to the fold differences in MICs, their magnitude was lower than that measured in vitro and depended on the specific resistance mechanism operating.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Single ERG11 point mutations do not provide the same degree of POS cross-resistance in C. albicans as in Aspergillus spp.
“single ERG11 point mutations do not provide the same degree of POS cross-resistance in C. albicans (MacCallum et al. 2010; Sanglard and Coste 2016; Warrilow et al. 2019).”
From Acquisition of cross-azole tolerance and aneuploidy in <i>Candida albicans</i> strains evolved to posaconazole (2022) · cites this paper as MacCallum et al. 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 33 · Cited by 98
- Authors
- MacCallum, D. M., Coste, A., Ischer, F., Jacobsen, M. D., Odds, F. C., & Sanglard, D.
- Affiliations
- University of Aberdeen (GB)
- Centre Hospitalier Universitaire Vaudois (CH)
- Institute of Microbiology, University of Lausanne and University Hospital Center, CH-1011 Lausanne, Switzerland
- Corresponding author
- Sanglard, Dominique
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-04
- Volume
- 54
- Issue
- 4
- Pages
- 1476-1483
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2849354
- OpenAlex
- W2128233423
- Cited by
- 98
- References
- 33
- Citations by year
- 2026: 1 · 2024: 1 · 2022: 3 · 2020: 3 · 2019: 6 · 2018: 10 · 2017: 8 · 2016: 9 · 2015: 13 · 2014: 5 · 2013: 12 · 2012: 10
- FWCI
- 8.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, azole resistance, fluconazole, ERG11, CDR1, CDR2, TAC1, multidrug transporter, cytochrome P450, ergosterol, invasive candidiasis, mouse model, antifungal susceptibility, clinical isolates
- MeSH terms
- Animals, Antifungal Agents, Base Sequence, Candida albicans, Candidiasis, Disease Models, Animal, DNA, Fungal, Female, Fungal Proteins, Genes, Fungal, Genetic Engineering, Humans, Mice, Inbred BALB C, Microbial Sensitivity Tests, Mutation, Fluconazole, DNA Primers, Drug Resistance, Fungal, Membrane Transport Proteins, Mice, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review